SCHEMBL7051915

SCHEMBL7051915

C=C(c1ccccc1)c1cncc2sc(C(N)=O)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 7/20 0.62
▸ PRKACA P17612 7/20 0.62
▸ GSK3A P49840 7/20 0.62
▸ GSK3B P49841 7/20 0.62
▸ DAPK3 O43293 6/20 0.62
▸ KDR P35968 6/20 0.62
▸ CDK5 Q00535 6/20 0.62
▸ RPS6KA3 P51812 6/20 0.62
▸ CDK1 P06493 6/20 0.62
▸ CDK2 P24941 6/20 0.62
▸ CSNK1D P48730 6/20 0.62
▸ DYRK1A Q13627 6/20 0.62
▸ PLK3 Q9H4B4 6/20 0.62
▸ SGK2 Q9HBY8 6/20 0.62
▸ LIMK1 P53667 5/20 0.62
▸ PLK4 O00444 5/20 0.62
▸ CHEK2 O96017 5/20 0.62
▸ MAPK9 P45984 5/20 0.62
▸ AURKB Q96GD4 5/20 0.62
▸ PLK1 P53350 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7053352 0.84 CSNK1D (0.53) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL7056141 0.82 ICAM1 (0.65) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL7056743 0.77 GSK3A (1.00) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL7056218 0.74 PIM1 (0.62) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL5550624 0.74 ICAM1 (1.00) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL7056216 0.74 PIM1 (0.62) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL5555083 0.74 ICAM1 (1.00) PIM1PRKACAGSK3AGSK3BKDR
SCHEMBL5554260 0.73 PIM1 (0.61) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL19769129 0.73 MAP3K8 (1.00) PIM1PRKACAGSK3AGSK3BDAPK3
SCHEMBL19780458 0.73 PIM1 (0.68) PIM1PRKACAGSK3AGSK3BDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 — — US claimed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 — — EP claimed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 — — US claimed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 — — EP claimed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 — — WO claimed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 — — WO claimed
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 — — US disclosed
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 — — US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 — — EP disclosed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 — — US disclosed
US-6232320-B1 THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES ABBOTT LABORATORIES 2001-05-15 — — US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 — — EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 — — WO disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM PIM1 2261/4885PRKACA 4020/4885GSK3A 3245/4885
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM PIM1 2261/4885PRKACA 4020/4885GSK3A 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback